Compare Chewy Inc (CHWY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chewy Inc vs Merck & Co., Inc. — how do they compare? Chewy Inc trades at $22.16 (market cap $9.20B), while Merck & Co., Inc. trades at $133.63 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 35× Chewy Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| CHWY | MRK | |
|---|---|---|
Market Cap | $9.20B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $131.84 |
52-Week Low | $17.51 | $77.60 |
Enterprise Value | $9.16B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chewy (CHWY) trades at $22.16, down 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $11.86B in 2025, with net income surging to $392.74M, though the net margin remains thin at 1.99%. Recent news highlights insider sales and institutional position changes, while analyst consensus remains strongly bullish with an 81.58% buy rating and a $33.82 price target.
The outlook is mixed: strong revenue growth and high ROE support upside potential, but thin margins, competitive pressures, and recent insider selling pose risks. Earnings beats in recent quarters provide momentum, yet the stock faces volatility near key support at $22. Investors should weigh robust analyst optimism against execution challenges in the pet care market.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
